Aslan Pharmaceuticals Ltd ASLN 深 沪
等待开盘 09-10 09:30:00 美东时间
0.60
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.60
- 总市值 169.70万
- 52周最高 22.16
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.475
- 委 比 0.00%
- 总股本 282.84万
- 历史最高 417.56
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.172
- 每 手 1
- 风险率 1.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) announced it will release its 2025 H1 unaudited interim results and provide business updates on August 20, 2025. Analysts and investors are invited to join webcasts with Q&A in Mandarin at 9:00 pm EDT/August 21, 2025 at 9:00 am HKT, or in English at 8:00 am EDT/August 21, 2025 at 8:00 pm HKT. The Company, focused on addressing unmet medical needs in cancer, has two approved products:...
08-07 12:00
Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement
Ascentage Pharma completed an offshore placement, raising approximately US$190.1 million through the sale of 22 million ordinary shares and subsequent issuance of replacement shares. Proceeds will fund commercialization, clinical development, and infrastructure to enhance global operations. The transaction adheres to regulatory requirements, and the replacement shares are expected to be issued by July 28, 2025.
07-17 08:30
Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
Ascentage Pharma announced the appointments of Veet Misra, Ph.D., as Chief Financial Officer, and Eric Huang as Senior Vice President of Global Corporate Development and Finance. Both will report to CEO Dajun Yang. Yang highlighted their expertise in advancing the company’s global strategy and operations. Misra brings deep scientific and capital markets experience, while Huang offers extensive corporate management and financial leadership. Ascent...
07-07 23:30
Why ASLAN Pharmaceuticals (ASLN) Shares Are Down 40%
ASLAN Pharmaceuticals shares are trading lower by 40.6% during Wednesday's session. The company announced that its Singapore-incorporated, sole operating subsidiary has filed for voluntary liquidation.
2024-07-18 00:10
ASLAN stock tumbles 54% after board votes to liquidate
ASLAN Pharmaceuticals (NASDAQ:ASLN) stock tumbled 54% early Wednesday after the company said it plans to liquidate and is exploring strategic options for its two primary drug assets, eblasakimab and f...
2024-07-17 22:12
ASLAN Pharmaceuticals Faces Nasdaq Delisting
Aslan Pharmaceuticals (ASLN) has released an update. ASLAN Pharmaceuticals, a b...
2024-07-15 19:54
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Shares of Vuzix Corporation (NASDAQ:VUZI) rose sharply in today's pre-market tr...
2024-06-20 20:22
ASLAN Pharmaceuticals Adjusts ADS Ratio
Aslan Pharmaceuticals (ASLN) has released an update. ASLAN Pharmaceuticals is s...
2024-06-15 05:58
ASLAN Pharmaceuticals announces plan to implement ADS ratio change
ASLAN Pharmaceuticals (NASDAQ:ASLN) on Friday said it plans to change the ratio of the American Depositary Shares to its ordinary shares, par value $0.01 per share, from one ADS representing twenty-fi...
2024-06-15 05:00
ASLAN Pharmaceuticals files to sell 61.9M ordinary shares for holders
ASLAN Pharmaceuticals (NASDAQ:ASLN) filed a prospectus related to the offer and resale of up to 61,904,761 ordinary shares. This prospectus is not an offer to sell. Filing More on ASLAN Pharmaceutical...
2024-06-13 04:41
